Skip to content

Vagus Nerve-guided Robotic-assisted Splenectomy and Azygoportal Disconnection

Vagus Nerve-guided Versus Conventional Robotic-assisted Splenectomy and Azygoportal Disconnection

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05300516
Acronym
VNRSD
Enrollment
60
Registered
2022-03-29
Start date
2022-04-01
Completion date
2023-07-31
Last updated
2026-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis, Hypertension, Robotic-assisted, Splenectomy

Keywords

Vagus nerve, Delayed gastric emptying, Cirrhosis, Hypertension, Robotic-assisted

Brief summary

This study aimed to evaluate whether vagus nerve-guided robotic-assisted splenectomy and azygoportal disconnection is effective and safe, and to determine whether a reduction in the incidence of postoperative complications of the digestive system improves postoperative quality of life compared with conventional robotic-assisted splenectomy and azygoportal disconnection.

Detailed description

After successful screening the cases of cirrhosis of liver irrespective of the etiology who have non tumor portal vein thrombosis will be enrolled. The baseline parameter will be recorded and the patient will be randomized into either interventional (vagus nerve-guided robotic-assisted splenectomy and azygoportal disconnection) or control (conventional robotic-assisted splenectomy and azygoportal disconnection) group. From postoperative day 3, all patients will receive 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months, low-molecular-weight heparin (CS Bio, Hebei, China) subcutaneously (4.100 IU/day) for 5 days, and 25 mg of oral dipyridamole (Henan Furen, Henan, China) thrice daily for 3 months. At months 3 after operation, electron gastroscopy examination for delayed gastric emptying will be done for all patients. Postoperative complications of the digestive system (including diarrhea, epigastric fullness, bloating, nausea, and vomiting), liver and renal function, and body weight will be recorded at the seventh day and months 3 after operation. Then 3 months monitoring will be done in the both groups as per the primary or secondary outcome.

Interventions

PROCEDUREvagus nerve-guided group

The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.

Sponsors

Northern Jiangsu People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. A clinical, radiological or histologic diagnosis of cirrhosis of any etiology 2. Splenomegaly with secondary hypersplenism 3. Bleeding portal hypertension 4. No evidence of portal vein system thrombosis by ultrasound evaluation and angio-CT 5. Informed consent to participate in the study

Exclusion criteria

1. Delayed gastric emptying 2. Diarrhea 3. Hepatocellular carcinoma or any other malignancy, 4. Hypercoagulable state other than the liver disease related 5. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs. 6. Child - Pugh C 7. Recent peptic ulcer disease 8. History of Hemorrhagic stroke 9. Pregnancy. 10. Uncontrolled Hypertension 11. Human immunodeficiency virus (HIV) infection

Design outcomes

Primary

MeasureTime frameDescription
Diarrhea3 monthProportions of patients who will suffer from diarrhea in both groups.
Delayed gastric emptying3 monthProportions of patients who will suffer from delayed gastric emptying in both groups.

Secondary

MeasureTime frameDescription
Postoperative complications of the digestive system3 monthProportions of patients who will suffer from postoperative complications of the digestive system in both groups.
Esophagogastric variceal re-bleeding3 monthProportions of patients who will suffer from esophagogastric variceal re-bleeding in both groups.

Countries

China

Contacts

STUDY_CHAIRDou-Sheng Bai, MD

Clinical Medical College, Yangzhou University

PRINCIPAL_INVESTIGATORGuo-Qing Jiang, MD

Clinical Medical College, Yangzhou University

STUDY_DIRECTORPing Chen, MD

Clinical Medical College, Yangzhou University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026